X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The safety analysis of CS-2034 (COVID-19 mRNA vaccine), showed that 28 days post booster vaccination, the overall incidence of adverse events was mainly mild in severity. Notably, the safety profile of elderly participants is better than that of participants aged 18-59.
Lead Product(s): COVID-19 mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CS-2034
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observed.
Lead Product(s): Homologous Inactivated Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia Air
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Aerogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
Lead Product(s): Convidecia
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Aerogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 09, 2021
Details:
Convidicea (Ad5-nCoV) is a novel recombinant viral vector vaccine for COVID-19 produced in China. The single-dose vaccine was developed on CanSinoBIO's adenovirus-based viral vector vaccine technology platform.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
CanSino developed the Ad5-nCoV vaccine that is currently approved for use in Mexico and Chile and is currently being tested in phase III trials in Argentina, under the supervision of ANMAT, the Argentine healthcare regulator.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2021
Details:
SPH CanSino will become the production base for Convidecia, the Covid-19 vaccine Ad5-nCoV for inhalation that has been approved by Chinese regulators for use under certain conditions and has been sanctioned for emergency use in Mexico, Pakistan, Hungary and Chile.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $171.2 million Upfront Cash: Undisclosed
Deal Type: Funding May 18, 2021
Details:
China’s CanSino Biologics will start clinical trials for a Covid-19 vaccine (Ad5-nCoV) administered through inhalation. Efficacy rates for China’s Covid vaccines have been found to be lower than those developed by Pfizer-BioNTech and Moderna.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Aerogen Solo
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
Convidecia™ has an efficacy of 90.07% at preventing severe disease 28 days after single dose vaccination, and 95.47% at preventing severe disease 14 days after single dose vaccination.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
CanSino Biologics' COVID-19 vaccine candidate is a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics and a team led by Chinese military infectious disease expert.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Aerogen Solo
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2021
Details:
Named Convidecia, the vaccine is made upon an adenovirus-based viral vector vaccine technology platform and uses a single-dose regime. It can be stably stored and transported between 2°C and 8°C.
Lead Product(s): Ad5-nCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: Convidecia
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
